Glucagon-like peptide-1: difference between revisions
Diff·revision 24 → 25·14:31, 15 Jun 2025
Difference between revision 24 and revision 25 of Glucagon-like peptide-1. 2 lines changed; the page grew by 201 bytes.
| Revision 24 — 12:09, 25 May 2025 UnitAuditUwe (talk) name the enzyme responsible for the cleavage at the first mention 11,229 bytes ±0 | Revision 25 — 14:31, 15 Jun 2025 AmylinAmos (talk) correct the second-messenger pathway named in the lead 11,430 bytes +201 | ||
|---|---|---|---|
| 76 | In type 2 diabetes the incretin effect is markedly attenuated. The dominant lesion appears to be loss of beta-cell responsiveness to GIP rather than deficient GLP-1 secretion, since pharmacological GLP-1 concentrations restore much of the insulin response whereas GIP does not.{{r|nauck1986,nauck2018}} This asymmetry is the reason the GLP-1 arm of the axis, and not the GIP arm, was pursued first as a monotherapy target — and it is also why the later demonstration that GIP co-agonism ''adds'' clinical benefit in [[Dual incretin agonist|dual agonists]] was regarded as surprising. | 76 | In type 2 diabetes the incretin effect is markedly attenuated. The dominant lesion appears to be loss of beta-cell responsiveness to GIP rather than deficient GLP-1 secretion, since pharmacological GLP-1 concentrations restore much of the insulin response whereas GIP does not.{{r|nauck1986,nauck2018}} This asymmetry is the reason the GLP-1 arm of the axis, and not the GIP arm, was pursued first as a monotherapy target — and it is also why the later demonstration that GIP co-agonism ''adds'' clinical benefit in [[Dual incretin agonist|dual agonists]] was regarded as surprising. |
| 77 | 77 | ||
| + | 78 | Whether GLP-1 secretion itself is reduced in obesity and type 2 diabetes has been contested for two decades; meta-analytic work suggests differences are small and heterogeneous between studies.{{cn}} | |
| + | 79 | ||
| 78 | == References == | 80 | == References == |
| 79 | {{reflist}} | 81 | {{reflist}} |